BioSyent Inc. announced changes to its executive management team: Effective on September 10, 2018, Mr. Alfred D'Souza has retired as Vice President, Finance and Chief Financial Officer of the company. Beyond September 10, 2018 date, Mr. D'Souza will ensure a smooth transition to his successor and will continue to act in an advisory capacity to the Company on an ongoing basis. Effective with Mr. D'Souza's retirement, Mr. Robert March has joined BioSyent as Vice President, Finance and Chief Financial Officer.

Prior to joining BioSyent, Robert accumulated over 15 years of progressive senior management experience in highly regulated industries in both Canada and the USA, most recently serving as Chief Financial Officer (and Co-Chief Operating Officer) for Ippolito Group of Companies. Mr. Joost van der Mark has also joined company's Executive Management team as Vice President, Corporate Development and will be responsible for business development and market access initiatives. Mr. van der Mark is a seasoned healthcare executive with over 20 years of experience in the biopharmaceutical industry.

Prior to joining company, Mr. van der Mark was the Chief Business Officer for 3D Signatures and previously, he co-founded Orphan Canada, which subsequently sold its assets to Knight Therapeutics in 2014.